Changes in myeloid-derived suppressor cells and cytokine expression during mother-to-child transmission prevention in HBeAg-positive pregnant women with chronic hepatitis B Authors: Shufang Pan, Lixin Xiao, Yiting Li, Yutian Chong, Jianyun Zhu, Chaoshuang Lin Published: 2026 ABSTRACT ObjectiveThe objective of this study was to investigate the changes of Myeloid-derived suppressor cells (MDSCs) and cytokines expression during mother-to-child blockade in chronic HBV infected patients.MethodThis was a single-center, prospective, observational study. From August 2020 to January 2021, 30 pregnant women with chronic hepatitis B (HBV DNA ≥ 5 log10 IU/mL) were enrolled, and their alanine aminotransferase was within the normal range. The period of mother-to-child blockade was divided into T0 (no antiviral treatment), T1 (antiviral treatment for 4 weeks) and T2 (antiviral treatment for 8 weeks). A total of 10mL of peripheral blood was obtained at that three different time points. Flow cytometry was utilized to assess the proportion of MDSCs within the peripheral blood mononuclear cells. Additionally, plasma samples were preserved for the analysis of inflammatory cytokine levels.ResultsThirty were initiated on antiviral therapy during 24–28 weeks of gestation and 19 were monitored for up to 8 weeks after antiviral therapy. The average HBV DNA titer was 8.03 log10 IU/mL at the beginning of antiviral therapy, and decreased to 3.53log10 IU/mL at 8 weeks after antiviral. After antiviral treatment, the percentage of MDSCs significantly decreased from 16.24% (range 2.26–29.12%) at baseline to 9.53% (range 3.89–17.30%) at week 4 and 2.20% (range 0.45–3.95%) at week 8 (repeated-measures ANOVA, P < 0.01). There was no statistically significant correlation between the percentage of MDSCs and the serum HBsAg and HBeAg levels before and after mother-to-children blockade. There was no statistically significant correlation between the percentage of MDSCs (and its subsets) and HBV DNA quantification during follow-up. IL-10 level was positively correlated with the percentage of MDSCs. IFN-γ level was negatively correlated with the percentage of MDSCs (P < 0.0001). There was no statistically significant correlation between IL-6 and, GM-CSF and the percentage of MDSCs.ConclusionsMDSCs tended to decrease during mother-to-child blockade during pregnancy in HBV chronically infected patients, and monocytic MDSCs was predominant. Inflammatory cytokines IL-6 and GM-CSF were not major contributors to MDSCs levels during pregnancy. Introduction Globally, an estimated 254 million individuals are living with chronic hepatitis B virus (HBV) infection [1]. While most adults clear acute infection, up to 90% of infants infected perinatally progress to chronic hepatitis [2]. Within this population, 15%-25% of individuals with untreated chronic hepatitis B will ultimately develop cirrhosis or hepatocellular carcinoma(HCC) [3]. The prevailing belief is that the absence or dysfunction of HBsAg-specific cytotoxic T-lymphocytes plays a significant role in the establishment of immune tolerance or suboptimal immune responses in individuals with chronic HBV infection [4]. Myeloid-derived suppressor cells (MDSCs) play a crucial role in mediating the intrinsic immune response by releasing a significant number of inhibitory molecules upon activation. This leads to the establishment of an immunosuppressive state within the body, facilitating the persistence of HBV infection and contributing to the progression of end-stage liver diseases, including hepatic fibrosis, cirrhosis, HCC, and other related conditions [5–7]. Patients in the chronic hepatitis B (CHB) group exhibited a higher abundance of MDSCs in comparison to healthy controls, with differential expression of MDSCs observed across various stages of chronic HBV infection [8]. Pregnant individuals with chronic HBV infection exhibit a dual immune-tolerant state characterized by chronic HBV infection and immunosuppression due to fetal-maternal immune tolerance. The precise mechanisms governing the clinical manifestations and serum markers of HBV disease activity, which are impacted by alterations in maternal immune status and function during mother-to-child transmission, remain poorly understood. Our hypothesis posits that alterations in immune cell levels during mother-to-child transmission in individuals with chronic HBV infection may modulate the host’s immunosuppressive milieu. During this period, the excessive immunosuppressive state would be alleviated. Therefore, we collected 30 pregnant women with chronic HBV infection to analyze and study the proportion of MDSCs in the peripheral blood, serum levels of the corresponding inflammatory cytokines, and the relationship with disease progression during mother-to-child blockade. Materials and methods Population Pregnant women in the immune tolerance phase of chronic hepatitis B, who sought care at the outpatient clinic of the Department of Infectious Diseases at the Third Affiliated Hospital of Sun Yat-sen University between August 2020 and January 2021, were enrolled in the study. Diagnosis was based on the criteria outlined in the 2019 edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B [9]. Eligible participants were: (1) Pregnant women with chronic HBV infection; (2) Serum HBV DNA ≥ 5 log₁₀ IU/mL; (3) Gestational age between 24 and 28 weeks at enrollment; (4) Willingness to participate and provide informed consent. The exclusion criteria for this study include: (1) concurrent infection with hepatitis A virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, or human immunodeficiency virus; (2) a history of antiviral therapy or concurrent treatment with immunomodulatory drugs, antitumor agents, cytotoxic drugs, or immunosuppressive steroids; and (3) identification of fetal malformations through three-dimensional ultrasonography. (4) Patients with decompensated liver disease and its complications (including coagulation disorders, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia, ascites, or variceal bleeding), hepatocellular carcinoma, or other chronic liver diseases (e.g., autoimmune hepatitis) were excluded from the trial. 5)a history of immune disorders. 6) severe cardiovascular disease. 7) Any additional conditions identified by the investigator as unsuitable for participation in the study will also be taken into consideration. All patients signed an informed consent form before inclusion in the study. The study was approved by the Ethics Review Board of the Third Affiliated Hospital of Sun Yat-sen University ([2019] 02-378-01). Methods All participants provided informed consent to receive antiviral treatment during the middle and late stages of gestation, opting for Tenofovir Alafenamide Fumarate tablets (TAF) at a dosage of 25 mg per day until delivery. The study defined the T0 period as the time prior to mother-to-child transmission prevention, the T1 period as 4 weeks post-antiviral initiation, and the T2 period as 8 weeks post-antiviral initiation. Levels of alanine aminotransferase (ALT), hepatitis B virus DNA (HBV DNA), hepatitis B surface antigen (HBsAg), and hepatitis B e antigen (HBeAg) were assessed at each stage. Peripheral blood samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes for analysis. Isolation of peripheral blood mononuclear cells (PBMCs) PBMCs were isolated using the Ficoll-Hypaque density gradient centrifugation method. Blood was diluted with PBS at a 1:1 ratio, followed by the slow addition of 4.5 ml of lymphocyte separation solution. The diluted blood was then layered above the liquid level to a total volume of 14mL. Centrifugation was conducted at 2000 rpm at room temperature for 20 min, with a speed up of 5 and speed down of 0. The mononuclear cell layer was collected, washed twice with PBS, and quantified. The cell concentration was adjusted to 1 × 106/mL before storage at -80℃. PBMCs were isolated and cryopreserved in freezing medium containing 10% dimethyl sulfoxide (DMSO) and 90% fetal bovine serum (FBS). Samples were stored at − 80 °C for short-term preservation (< 12 weeks). Following thawing, cell distribution and viability were assessed by flow cytometry. Only samples with normal cell distribution and low proportions of dead cells were included in downstream analyses. Flow cytometry Freshly isolated PBMCs or PBMCs stored at -80℃ were retrieved for subsequent use. In the case of frozen PBMCs, cell resuscitation was necessary prior to further processing. The resuscitated cell suspension was transferred to a 15 mL centrifuge tube along with 5 mL of RPMI-1640 medium, mixed, and centrifuged at 18 °C and 112 × g for 5 min (equivalent to 1000 rpm with a rotor radius of 10 cm), followed by removal of the supernatant. Subsequently, 3mL of RPMI 1640 medium was added, thoroughly mixed, and transferred into a clean flow tube in 500uL aliquots. After another round of centrifugation, the supernatant was discarded, leaving 100uL of liquid, and the cells were gently patted and shaken to ensure even dispersion. During the antibody incubation process, a blank tube and a single dye tube were prepared as follows: CD33-PE (clone P67.6, BD Biosciences), CD11b-FITC (clone ICRF44, BD Biosciences), HLA-DR-APC (clone LN3, eBioscience), CD15-BV421 (clone SSEA-1, BioLegend), and CD14-PE-Cy7 (clone 61D3, eBioscience). Data were acquired on a BD FACSCanto II and analyzed with FlowJo software. The gating hierarchy was as follows: (i) exclusion of debris by forward/side scatter, (ii) singlet discrimination, (iii) selection of HLA-DR⁻ cells, (iv) identification of CD33⁺CD11b⁺ MDSCs, and (v) subdivision into monocytic (CD14⁺) and granulocytic (CD15⁺) MDSCs. A representative gating strategy is provided in Fig. 2 (A-C). During flow cytometry analysis, mononuclear cells were clearly identified based on FSC/SSC characteristics and singlet gating. A live/dead viability dye was not included in the panel. Enzyme-linked immunosorbent (ELISA) assay Plasma samples were collected and stored at -80 °C prior to analysis. The levels of IL-10, IFN-γ, IL-6, and GM-CSF were quantified using ELISA kits obtained from Sino Biological, following the manufacturer’s instructions. Absorbance readings were taken at 450 nm using a microplate reader (BioTek ELX800, USA). Statistical analysis Experimental data were organized using Microsoft Excel (Microsoft Corp., Redmond, WA, USA). Statistical analyses were performed with SPSS version 25.0 (IBM Corp., Armonk, NY, USA), and figures were generated using GraphPad Prism version 7 (GraphPad Software, San Diego, CA, USA). Normality of continuous variables was assessed using the Shapiro–Wilk test. For repeated measurements obtained at T0, T1, and T2 from the same participants, repeated-measures ANOVA was applied when assumptions of normality and sphericity were met; otherwise, the nonparametric Friedman test was used. Post-hoc pairwise comparisons were conducted with Bonferroni correction (for ANOVA) or Dunn’s test (for Friedman). Between-group differences were analyzed using one-way ANOVA or Mann–Whitney U tests, as appropriate. Correlations were assessed using Spearman’s rank correlation coefficient. A two-tailed p-value < 0.05 was considered statistically significant. Results A total of 30 cases were included in the study, with a gestation period ranging from 24 to 28 weeks and an age range of 22 to 36 years, with a mean age of 30.5 years. All patients exhibited normal ALT levels, HBV DNA levels exceeding 5log10 IU/mL, with a mean of 8.03log10 IU/mL, and were positive for HBeAg (see Table 1). Exclusion criteria included other forms of viral hepatitis, as well as heart, brain, kidney, or other systemic diseases, and pregnancy-related conditions. Due to the impact of the COVID-19 pandemic, some patients were lost to follow-up, resulting in a final cohort of 19 subjects who were monitored until 36–38 weeks of gestation (see Fig. 1). Table 1Laboratory features of study groups across different time pointsTimeALT, U/LHBV DNA*, IU/mLHBsAg, IU/mLHBeAg, IU/mLT0 (n = 30)22.50 (15.75, 30.5)8.04 ± 0.6718674.00 (11352.00, 32031.50)1572.50 (1251.75, 1661.00)T1 (n = 30)18.50 (15.75, 23.00)4.86 ± 0.7615446.00 (8633.25, 28725.75)1533.00 (976.25, 1626.75)T2 (n = 19)18.00(13.00, 23.00)3.53 ± 0.8113297.00 (5436.00, 22535.00)1448.00 (255.00, 1597.00)*: HBV DNA are presented as log10-transformed data Table 1Laboratory features of study groups across different time pointsTimeALT, U/LHBV DNA*, IU/mLHBsAg, IU/mLHBeAg, IU/mLT0 (n = 30)22.50 (15.75, 30.5)8.04 ± 0.6718674.00 (11352.00, 32031.50)1572.50 (1251.75, 1661.00)T1 (n = 30)18.50 (15.75, 23.00)4.86 ± 0.7615446.00 (8633.25, 28725.75)1533.00 (976.25, 1626.75)T2 (n = 19)18.00(13.00, 23.00)3.53 ± 0.8113297.00 (5436.00, 22535.00)1448.00 (255.00, 1597.00)*: HBV DNA are presented as log10-transformed data Laboratory features of study groups across different time points *: HBV DNA are presented as log10-transformed data Fig. 1Flowcart Flowcart The percentage of peripheral blood MDSC in chronically infected HBV patients showed a decreasing trend during mother-to-child block during pregnancy The mean MDSCs percentage in mononuclear cells was 16.24% (range 2.26% to 29.12%) at T0. The mean value of T1 stage was 9.53% (range 3.89% to 17.30%); The mean value of T2 stage was 2.20% (range 0.45% to 3.95%) (Fig. 2). Further subgroup analysis revealed distinct dynamics between monocytic and granulocytic MDSCs. At baseline (T0), the mean percentage of M-MDSCs was 13.31% (range 1.90–27.69%), whereas G-MDSCs accounted for 0.21% (range 0.02–1.08%). At T1, M-MDSCs decreased to a mean of 6.81% (range 1.17–14.25%), while G-MDSCs slightly increased to 0.35% (range 0.11–0.68%). By T2, M-MDSCs further declined to 1.73% (range 0.24–3.62%), whereas G-MDSCs rose modestly to 0.44% (range 0.02–0.99%). Thus, M-MDSCs consistently exhibited a downward trend during mother-to-child blockade, while G-MDSCs showed a slight but statistically significant increase between T0 and T2 (p < 0.05, Table 2). These findings indicate that although the overall MDSC burden decreased, the relative composition of MDSC subsets shifted, with G-MDSCs becoming proportionally more prominent. Fig. 2The percentage of peripheral blood MDSC in chronically infected HBV patients during mother-to-child block during pregnancy. (A) Representative flow cytometry images of MDSC in T0; (B) Representative flow cytometry images of MDSC in T1; (C) Representative flow cytometry images of MDSC in T2. (D) Comparison of the percentage of MDSC in mononuclear cells The percentage of peripheral blood MDSC in chronically infected HBV patients during mother-to-child block during pregnancy. (A) Representative flow cytometry images of MDSC in T0; (B) Representative flow cytometry images of MDSC in T1; (C) Representative flow cytometry images of MDSC in T2. (D) Comparison of the percentage of MDSC in mononuclear cells Table 2Changes in the percentage of MDSC subgroup during mother-to-child blockTimeMDSCsM-MDSCsG-MDSCsT016.24%±7.35%12.36% (7.63%, 18.02%)0.11% (0.04%, 0.28%)T19.42%±3.97%8.1% (6.26%, 12.87%)0.37% (0.21%, 0.44%)T22.2%±0.98%1.49% (1.10%, 2.23%)0.54% (0.06%, 0.76%) Table 2Changes in the percentage of MDSC subgroup during mother-to-child blockTimeMDSCsM-MDSCsG-MDSCsT016.24%±7.35%12.36% (7.63%, 18.02%)0.11% (0.04%, 0.28%)T19.42%±3.97%8.1% (6.26%, 12.87%)0.37% (0.21%, 0.44%)T22.2%±0.98%1.49% (1.10%, 2.23%)0.54% (0.06%, 0.76%) Changes in the percentage of MDSC subgroup during mother-to-child block Correlation between the percentage of MDSC and HBsAg, HBeAg and HBV DNA in chronically infected HBV patients during mother-to-child block during pregnancy Correlation between MDSC percentage and HBsAg quantification In this investigation, the serum HBsAg levels of patients were examined before (T0) and after (T1 + T2) occlusion, along with the corresponding percentages of MDSC/monocytes. The statistical analysis revealed no significant correlation between the serum HBsAg levels and the corresponding percentages of MDSC/monocytes at the T0 stage (P = 0.3553, Spearman r=-0.1749) and the combined T1 and T2 stages (P = 0.8332, Spearman r = 0.3533) (Fig. 3A). Correlation between MDSC percentage and HBeAg quantification In this study, the serum HBeAg quantity of the patients before (T0) and after (T1 + T2) occlusion and the corresponding %MDSC/monocytes were statistically analyzed. The findings indicated that there was no statistically significant association between the serum HBeAg level and the corresponding %MDSC/monocytes prior to and following the maternal-to-child block (T0) (T1 + T2) [(T0: P = 0.3828, Spearman r = -0.1653), (T1 + T2: P = 0.5776, Spearman r = 0.09326)] (Fig. 3B). Correlation between MDSC percentage and HBV DNA quantification In this study, only the correlation between the percentage of MDSC (and its subsets) in the peripheral blood of chronic HBV infected patients at stage T0 (before mother-to-child block) and the log value of HBV DNA copy number was statistically analyzed for the patients in the group. Because the antiviral drugs during T1 and T2 would affect the change of HBV DNA. The results showed that there was no statistically significant correlation between the percentage of MDSC in mononuclear cells and the HBV DNA in pregnant women with chronic HBV infection during pregnancy (P = 0.5385, Spearman r=-0.1169). There was no statistical correlation between the percentages of M-MDSC, G-MDSC subgroups and HBV DNA (M-MDSC: P = 0.8822, Spearman r=-0.02826;G-MDSC༚P = 0.2084, Spearman r = 0.2364) (Fig. 3C). Fig. 3Correlation between the percentage of MDSCs and HBsAg, HBeAg and HBV DNA. (A) Correlation between the percentage of MDSCs in mononuclear cells and serum HBsAg quantification during T0 or T1 + T2. (B) Correlation between the percentage of MDSCs in mononuclear cells and serum HBeAg quantification during T0 or T1 + T2. (C) Correlation between the percentage of MDSCs (including M-MDSC and G-MDSC) in mononuclear cells and HBV DNA Correlation between the percentage of MDSCs and HBsAg, HBeAg and HBV DNA. (A) Correlation between the percentage of MDSCs in mononuclear cells and serum HBsAg quantification during T0 or T1 + T2. (B) Correlation between the percentage of MDSCs in mononuclear cells and serum HBeAg quantification during T0 or T1 + T2. (C) Correlation between the percentage of MDSCs (including M-MDSC and G-MDSC) in mononuclear cells and HBV DNA Correlation between the percentage of MDSC and IL-6, IL-10, IFN-γ and GM-CSF in chronically infected HBV patients during mother-to-child block during pregnancy Changes in IL-6 levels during the decrease of the percentage of MDSCs The ELISA method was utilized in this study to measure serum IL-6 levels in patients within the case group at T0, T1, and T2 stages. The findings indicated that there was no significant decrease in IL-6 levels during antiviral treatment compared to levels at T0, T1, and T2 stages (P > 0.05). Additionally, the correlation analysis between the percentage of MDSCs and IL-6 levels revealed no statistical significance (P = 0.3405, Spearman r = 0.1322) (Fig. 4A). Changes in IL-10 levels during the decrease of the percentage of MDSCs The results indicate that patients in the T0 stage group exhibited a significantly higher serum IL-10 level compared to those in the T1 stage group (P < 0.01). Additionally, there was no significant decrease in serum IL-10 levels between the T1 and T2 stages (P = 0.1591). Furthermore, a positive correlation was observed between the percentage of myeloid-derived suppressor cells (MDSCs) in mononuclear cells in peripheral blood and IL-10 content in the same cases (P = 0.0462, Spearman r = 0.355) (Fig. 4B). Changes in IFN-γ levels during the decrease of the percentage of MDSCs The study observed a significant increase in serum IFN-γ levels as MDSCs levels decreased (P < 0.05). Additionally, a negative correlation was found between the percentage of MDSCs and serum IFN-γ levels, with a statistically significant result (P < 0.0001, Spearman r=-0.6588) (Fig. 4C). Changes in GM-CSF levels during the decrease of the percentage of MDSCs During the antiviral treatment, there was no significant decrease in the level of GM-CSF at T1 and T2 stages compared to T0 (all P > 0.05). Additionally, the correlation analysis between the percentage of MDSCs and GM-CSF level did not yield statistically significant results (P = 0.6406, Spearman r = 0.06436) (Fig. 4D). Fig. 4Correlation between the percentage of MDSCs and IL-6, IL-10, IFN-γ and GM-CSF. (A) Changes in IL-6 levels during the decrease of the percentage of MDSC. (B) Changes in IL-10 levels during the decrease of the percentage of MDSCs. (C) Changes in IFN-γ levels during the decrease of the percentage of MDSCs. (D) Changes in GM-CSF levels during the decrease of the percentage of MDSCs Correlation between the percentage of MDSCs and IL-6, IL-10, IFN-γ and GM-CSF. (A) Changes in IL-6 levels during the decrease of the percentage of MDSC. (B) Changes in IL-10 levels during the decrease of the percentage of MDSCs. (C) Changes in IFN-γ levels during the decrease of the percentage of MDSCs. (D) Changes in GM-CSF levels during the decrease of the percentage of MDSCs Discussion In this study, we selected TAF as the mother-to-child blocking drug for CHB pregnancy on the basis of domestic and foreign studies and the approval of ethical applications. By flow cytometry, the expression changes of the percentage of MDSCs in peripheral blood mononuclear cells during mother-to-child block in patients with chronic hepatitis B during pregnancy were analyzed and compared with the clinical indicators. The concentrations of the inflammatory cytokines IL-10 and IFN-γ were measured using ELISA and their relationship with the percentage of MDSCs was assessed. Additionally, the impact of IL-6 and GM-CSF on alterations in MDSCs levels throughout pregnancy was investigated, offering valuable insights for future research on the modulation of maternal and fetal immune cell levels and immune responses during gestation. During the process of mother-to-child block, our study revealed a notable decrease in the level of MDSCs, with M-MDSC being the predominant subset. Serum levels of HBsAg and HBeAg did not exhibit a significant relationship with the percentage of MDSCs before and after transmission. Furthermore, there was no statistically significant association between MDSCs levels and HBV DNA quantification, as well as with its subsets M-MDSC and G-MDSC. These findings slightly deviate from previous research conclusions, possibly due to the limited sample size in our study and other confounding factors. In normal pregnancy, MDSCs—particularly G‑MDSCs—increase markedly in both peripheral blood and the maternal–fetal interface during early gestation [10], where they suppress Th1‑type immunity (e.g., IFN‑γ production) and promote Th2‑ and regulatory responses to facilitate embryo implantation and prevent maternal immune rejection. During mid‑pregnancy, MDSC levels remain elevated, accompanied by enhanced secretion of IL‑10 and TGF‑β [11], thereby sustaining immune tolerance. In late pregnancy, overall MDSC levels gradually decline, although they remain higher than in non‑pregnant women; M‑MDSCs tend to decrease, whereas G‑MDSCs may persist at relatively higher proportions, consistent with the partial reactivation of maternal immunity prior to delivery [12]. After childbirth, MDSC levels typically return to baseline within several days [10]. Patients with chronic hepatitis B, however, exhibit an intrinsically elevated MDSC profile dominated by G‑MDSCs, which contributes to impaired T‑cell function [13]. Antiviral therapy with nucleos(t)ide analogues generally leads to a reduction in total MDSCs and a decline in the G‑MDSC fraction, reflecting partial restoration of T‑cell immunity [14]. In our study, participants were enrolled at 24–28 weeks of gestation, corresponding to the mid‑to‑late pregnancy period when MDSC levels are physiologically high. By the time of the two follow‑up visits after initiation of TAF therapy, patients had progressed into late pregnancy, making the observed decline in total MDSCs biologically plausible. However, the proportion of G‑MDSCs did not decrease substantially and even showed a relative increase in some cases, likely reflecting the unique role of G‑MDSCs in maintaining maternal–fetal immune tolerance during late gestation. It has been found that IL-6 and GM-CSF can induce the amplification of MDSCs. Melissa G induced CD33+ MDSC in vitro through 15 kinds of immune factors (TGF-β, IL-10β, IL-4, IL-6, IL-10, GM-CSF, M-CSF, IDO, iNOS, arginase-1, TNF-α, VEGF, etc.). By measuring its ability to inhibit T cell proliferation and IFN-γ production, immune factors inducing MDSCs amplification can be inferred. The results showed that IL-6 and GM-CSF could successfully induce CD33+ MDSCs in vitro, and had the ability to inhibit T cell activation and IFN-γ production, which was similar to human MDSCs. Therefore, they concluded that IL-6 and GM-CSF could induce the amplification of MDSCs [15]. It remains unclear whether IL-6 and GM-CSF impact changes in MDSCs levels during pregnancy. In this study, the changes of IL-6 and GM-CSF levels during mother-to-child block (the decline of MDSCs percentage) during pregnancy were detected by ELISA, and the results showed that there was no significant trend of changes in both IL-6 and GM-CSF levels, and there was no statistically significant correlation between the levels of IL-6 and GM-CSF and the percentage of MDSCs. In light of these findings, it can be posited that IL-6 and GM-CSF do not represent the primary influencing factors responsible for the observed alterations in MDSCs levels. Rather, it is plausible that MDSCs may be subject to the influence of specific hormonal fluctuations and distinctive physiological states that accompany pregnancy. This conclusion aligns with the observations reported by Pan [16]. As an immunosuppressive factor, IL-10 can inhibit the production of a variety of cytokines and inhibit the response of Th1 cells. Studies have confirmed that IL-10 levels in patients with chronic hepatitis B are higher than those in normal population, and are positively correlated with ALT and HBV DNA quantification [17]. In this study, IL-10 showed a downward trend within first month of taking the drug, but the downward trend was no longer obvious with the antiviral process. IL‑10 levels were also positively correlated with the proportion of MDSCs, indicating that lower MDSC frequencies during pregnancy are accompanied by reduced IL‑10 production. This observation is consistent with reports showing that Breg cells produce high levels of IL‑10 in early pregnancy, followed by a gradual decline from mid‑pregnancy onward, although IL‑10 production is maintained at a relatively stable level thereafter [18]. IFN-γ, as a pleiotropic cytokine, plays an important antiviral role in the immune activation phase of chronic hepatitis B. While in the immune tolerance phase, IFN-γ level is inhibited [19]. Studies have confirmed that the level of IFN-γ in patients with chronic hepatitis B is significantly lower than that in healthy people, and MDSCs can significantly inhibit the production of IFN-γ by Th1 cells [20]. In the present study, a significant positive correlation was observed between IFN-γ levels and the progression of antiviral therapy, while a negative correlation was found with the percentage of MDSCs. It can be concluded that a lower level of MDSCs corresponds to a higher level of IFN-γ, indicating a reduction in immune suppression and increased immune activation during the mother-to-child transmission block in pregnancy. This study has several limitations that should be acknowledged. First, the relatively small sample size may limit statistical power and the generalisability of the findings. Second, the single‑centre design may reduce external validity. Third, loss to follow‑up, partly attributable to pandemic‑related constraints, may have introduced attrition bias. Fourth, the absence of a healthy pregnant control group, combined with the dynamic fluctuations of MDSC levels throughout pregnancy, further constrains the interpretability of the results. Fifth, the short duration of follow‑up—restricted to 8 weeks after initiation of therapy and ending at delivery—precludes assessment of the long‑term stability of the observed immunological changes. It remains unclear whether alterations in MDSCs and cytokine profiles persist after childbirth, after discontinuation of antiviral therapy, or following the resolution of pregnancy‑induced immunosuppression. Finally, the storage conditions and handling of PBMC samples may have affected cellular integrity and contributed to measurement variability. Taken together, these factors suggest that the present findings should be interpreted as preliminary. Larger, multi‑centre studies with extended postpartum follow‑up and appropriate control groups are needed to validate and extend these observations. In summary, our hypothesis posited that the mother-to-child blockade of chronic HBV infection during pregnancy may lead to alterations in immune cell levels and cytokine profiles as a result of the unique physiological state of pregnancy, consequently impacting the immune status. Particularly noteworthy was the significant change observed in the percentage of MDSCs, with a notable decrease in overall MDSCs levels during this period, predominantly consisting of M-MDSCs. There was no statistically significant correlation observed between the percentage of MDSCs and HBV serological markers, such as HBsAg and HBeAg, before and after mother-to-child transmission. This lack of correlation may be attributed to the limited number of cases, short duration of follow-up, and the modest impact of short-term antiviral therapy on the quantification of HBeAg and HBsAg. Additionally, during mother-to-child transmission, there was a decreasing trend in the levels of IL-10, with a positive correlation noted between the percentage of MDSCs and IL-10 levels. The correlation between the percentage of MDSCs and IFN-γ levels was found to be negative. Conversely, levels of IL-6 and GM-CSF remained stable during mother-to-child transmission, with no statistically significant correlation observed with MDSC percentage. Consequently, it was concluded that IL-6 and GM-CSF were probably not the primary influencing factors on changes in MDSC levels during pregnancy.